United Services Automobile Association Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• United Services Automobile Association has acquired a new stake in Zimmer Biomet Holdings, purchasing 4,681 shares valued at approximately $525,000.
• Zimmer Biomet's recent quarterly earnings exceeded expectations with a reported $2.07 earnings per share and revenue of $2.08 billion, marking a 7.0% increase from the previous year.
• The company declared a quarterly dividend of $0.24 per share, reflecting an annualized yield of 0.9% with a payout ratio of 23.36%.

United Services Automobile Association acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,681 shares of the medical equipment provider's stock, valued at approximately $525,000.

Several other large investors also recently made changes to their positions in the stock. Ashton Thomas Private Wealth LLC boosted its holdings in shares of Zimmer Biomet by 13.4% in the 1st quarter. Ashton Thomas Private Wealth LLC now owns 10,280 shares of the medical equipment provider's stock valued at $1,166,000 after buying an additional 1,218 shares during the last quarter. USS Investment Management Ltd boosted its holdings in shares of Zimmer Biomet by 7.8% in the 1st quarter. USS Investment Management Ltd now owns 50,466 shares of the medical equipment provider's stock valued at $5,713,000 after buying an additional 3,642 shares during the last quarter. UniSuper Management Pty Ltd boosted its holdings in shares of Zimmer Biomet by 1.0% in the 1st quarter. UniSuper Management Pty Ltd now owns 24,025 shares of the medical equipment provider's stock valued at $2,719,000 after buying an additional 242 shares during the last quarter. Sandler Capital Management acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at approximately $4,731,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at approximately $22,693,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Zimmer Biomet Stock Down 1.5%

ZBH stock opened at $102.33 on Thursday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The stock has a market capitalization of $20.27 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 2.05 and a beta of 0.68. The business's fifty day moving average price is $99.06 and its two-hundred day moving average price is $99.63. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $114.72.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The firm had revenue of $2.08 billion for the quarter, compared to analysts' expectations of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet's dividend payout ratio (DPR) is presently 23.36%.

Wall Street Analyst Weigh In

ZBH has been the subject of several recent analyst reports. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Raymond James Financial increased their price target on Zimmer Biomet from $104.00 to $113.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. Royal Bank Of Canada increased their price target on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a research note on Friday, August 8th. UBS Group increased their price target on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a research note on Friday, August 8th. Finally, Evercore ISI dropped their price target on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Nine research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $111.00.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.39% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.